Knight and Ember Expand Distribution Partnership
GlobeNewswire - Wed Jul 06, 7:08AM CDT
Knight Therapeutics Inc. (TSX:GUD) ("Knight"
GUD.TO: 8.25 (-0.10)
Ember Therapeutics to Present at Marcum MicroCap Conference
GlobeNewswire - Tue May 31, 12:31PM CDT
Ember Therapeutics, Inc. (OTCQB:EMBT), a New York-based biopharmaceutical company developing targeted therapies for osteoarthritis, kidney fibrosis, and other indications using Bone Morphogenetic Protein (BMP)-7, today announced that the Company is scheduled to present at the 2016 Marcum MicroCap Conference being held June 1-2, 2016 in New York, NY.
Ember Therapeutics Acquires Migralex(TM)
GlobeNewswire - Mon Mar 21, 8:33AM CDT
Ember Therapeutics, Inc. (OTCQB:EMBT), a New York-based pharmaceutical company developing targeted therapies for osteoarthritis, kidney fibrosis, and other regenerative medicines, today announced that it has entered into a definitive agreement for the acquisition of Migralex(TM), a commercially available over-the-counter medication for treating pain.
Ember Therapeutics Enhances Regenerative Medicine Pipeline With Acquisition of ICX-RHY/Vavelta(TM) from Intercytex
GlobeNewswire - Wed Mar 16, 7:30AM CDT
Ember Therapeutics, Inc. (OTCQB:EMBT), a New York-based biopharmaceutical company developing targeted therapies for osteoarthritis, kidney fibrosis, and other indications using Bone Morphogenetic Protein (BMP)-7, today announced the acquisition of ICX-RHY/Vavelta(TM), a regenerative medicine asset, from Intercytex.